Fuhong Hanlin (02696): The application for marketing approval of Hanshiu combined chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer has been accepted by the National Medical Products Administration (NMPA) and has been included in priority review.

The Smart Financial APP announced that Fosun Pharma (02696) has released a statement. Recently, the company's independently developed Hansloy (sulilumab injection) for combination with platinum-based chemotherapy as neoadjuvant therapy after surgery, for the treatment of PD-L1 positive, operable gastric cancer patients, has had its new drug application (NDA) accepted by the National Medical Products Administration (NMPA) Drug Evaluation Center, and has been included in the priority review and approval process to accelerate its market approval process.